Marina Biotech to close Cambridge site

Thursday, February 16, 2012 06:33 AM

Marina Biotech, a nucleic acid-based drug discovery and development company, will be closing its Cambridge, Mass., site and consolidating all R&D efforts at its headquarters in Bothell, Wash.

"This move will not affect the START-FAP trial as noted by our announcement of cohort II dosing. Further, we expect to continue to develop the tkRNAi platform in our labs in Bothell," said J. Michael French, president and CEO of Marina Biotech.

The individuals affected by the decision were all part of the former Cequent team, who helped develop CEQ508 and executed the START-FAP trial.

“I want to thank them for their efforts and wish them all well in their future endeavors," added French.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs